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Abstract
Background: Regulation of pain states is, in part, dependent upon plastic changes in neurones
within the superficial dorsal horn. There is also compelling evidence that pain states are under the
control of descending projections from the brainstem. While a number of transcription factors
including Methyl-CpG-binding protein 2 (MeCP2), Zif268 and Fos have been implicated in the
regulation of dorsal horn neurone sensitization following injury, modulation of their activity by
descending controls has not been investigated.
Results:  Here, we describe how descending controls regulate MeCP2 phosphorylation (P-
MeCP2), known to relieve transcriptional repression by MeCP2, and Zif268 and Fos expression in
the rat superficial dorsal horn, after CFA injection into the hind paw. First, we report that CFA
significantly increased P-MeCP2 in Lamina I and II, from 30 min post injection, with a maximum
reached after 1 h. The increase in P-MeCP2 paralleled that of Zif268 and Fos, and P-MeCP2 was
expressed in large sub-populations of Zif268 and Fos expressing neurones. Serotonergic depletion
of the lumbar spinal cord with 5,7 di-hydroxytryptamine creatinine sulphate (5,7-DHT) reduced the
inflammation evoked P-MeCP2 in the superficial dorsal horn by 57%, and that of Zif268 and Fos by
37.5% and 30% respectively. Although 5,7-DHT did not change primary thermal hyperalgesia, it
significantly attenuated mechanical sensitivity seen in the first 24 h after CFA.
Conclusion: We conclude that descending serotonergic pathways play a crucial role in regulating
gene expression in the dorsal horn and mechanical sensitivity associated with an inflammatory pain
state.
Background
The development and maintenance of pain states are
dependant upon plastic changes in neurones of the super-
ficial dorsal horn that are thought to be under the control
of descending pathways originating in the brainstem
[1,2]. The transcription factors Fos, Zif268 and Methyl-
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CpG-binding protein 2 (MeCP2) have been implicated in
dorsal horn plasticity yet their dependence on descending
controls for their full activation has not been explored.
MeCP2 is a transcriptional repressor that regulates activ-
ity-dependent gene transcription and is critical for normal
neurological function. Mutations in human MeCP2 result
in the neurodevelopmental disorder Rett syndrome [3,4].
However, we know very little about the physiological role
of MeCP2 in the central nervous system. MeCP2 regulates
gene transcription by binding to methylated CpG dinucle-
otides and recruiting co-repressors such as histone
deacetylases to promote chromatin compaction and
reduce access of transcription factors to promoter DNA
[5].  In vitro, phosphorylation of MeCP2 at S421 was
shown to lead to the displacement of MeCP2 from the
BDNF promoter resulting in an increase in BDNF expres-
sion [6]. We recently showed that MeCP2 was phosphor-
ylated in the rat superficial dorsal horn after induction of
peripheral joint inflammation, leading to an increase in
expression of a family of genes under transcriptional con-
trol by MeCP2. These included the serum- and glucocorti-
coid- regulated kinase (SGK1) which we found was
involved in the induction of pain states [7]. Numerous
studies also support a role for Fos and Zif268, a transcrip-
tion factor essential for the maintenance of longer term
LTP in the hippocampus, in the initiation and mainte-
nance of pain states [8,9].
Descending controls have been shown to play a crucial
role in the regulation of pain states [10]. We therefore
considered the possibility that the changes in gene expres-
sion that follow activation of transcription factors in the
dorsal horn are the result of converging patterns of activity
and not simply a response to primary afferent stimula-
tion. Serotonergic controls are essential for the mainte-
nance of neuropathic pain states and the full development
of ERK activation, a kinase essential for the development
of central sensitization [11,12]. We have therefore investi-
gated the contribution of serotonergic inputs to the activa-
tion of transcription factors MeCP2, Zif268 and Fos as
well as on the development of mechanical and thermal
hyperalgesia induced by peripheral inflammation. A
number of serotonergic receptors and descending sero-
tonergic pathways have been implicated in the mainte-
nance of pain states [13]. We therefore investigated the
regulation of transcription factors after depletion of spinal
5-HT using 5,7 di-hydroxytryptamine creatinine sulphate
(5,7-DHT). We found that serotonergic controls partici-
pated in both the activation of transcription factors and
the mechanical hypersensitivity that develops in the first
hours after inflammation.
Methods
Animals' preparation
All procedures complied with the UK Animals (Scientific
Procedures) Act 1986. Experiments were carried out on
male Sprague-Dawley rats (180–250 g body weight) from
the colony at University College London. All efforts were
made to minimise animal suffering and to reduce the
number of animals used. Inflammation was induced by
injection of Complete Freund's Adjuvant (CFA, Sigma,
Pool, UK; 50 μl) in the left hind paw, under halothane
anaesthesia.
Immunohistochemistry
Rats were perfused as described [7] and lumbar spinal
cord was dissected out and cut on a freezing microtome
set at 40 μm. The antibodies were revealed by diami-
nobenzidinetetrahydrochloride (DAB, peroxidase sub-
strate) or fluorescent immunohistochemistry, as
appropriate. For DAB reactions, sections were left to incu-
bate with primary antibodies for 48 h at 4°C (P-MeCP2,
S421; 1:10,000; a gift from Zhaolan Zhou and Michael
Greenberg) or overnight at room temperature (Fos, Onco-
gene, 1:60,000 and Zif268, Santa Cruz sc-189, 1:10,000)
followed by conventional DAB protocol. For MeCP2 fluo-
rescent immunohistochemistry, we followed a protocol of
TSA amplification as described previously [7]. For double
labelling with Zif268 and Fos, sections stained for P-
MeCP2 were left for 24 h at room temperature in a solu-
tion of Zif268 (1:5000) or Fos (1:5000) antibody. Direct
secondary was used at a concentration of 1:500 (Anti-rab-
bit Alexa 594). Both NeuN (a specific neuronal marker;
Chemicon; 1:1000, 24 h room temperature) and GFAP
(Dako, 1:4000, 24 h room temperature) were revealed
using direct secondary as described above. 5-HT (Chemi-
con; 1:75; 24 h room temperature) was revealed using a
biotinylated secondary antibody (1:500 for 2 h) followed
by streptavidin conjugated Cy3 (Jackson Laboratories; 1:4
000; 45 min). Controls for immunohistochemistry
included omitting the first or second primary antibodies.
Intrathecal administration of 5,7 di-hydroxytryptamine
5,7 di-hydroxytryptamine creatinine sulphate (5,7-DHT;
Sigma-Aldrich) was administered via intrathecal injection
as described [11]. To prevent toxicity to noradrenergic
neurones, rats received desipramine (a noradrenaline
reuptake inhibitor; Sigma-Aldrich; 25 mg/kg) 1 h prior to
5,7-DHT administration. Animals received either 10 μl of
5,7-DHT (60 μg) or saline 0.9%.
Behavioural assay
For each behavioural assay, animals were habituated over
a period of 3 consecutive days by recording a series of
baseline measurements. Animals were allowed to habitu-
ate to the experimental room for 10–15 min before testing
began. Four readings were collected per animal with anMolecular Pain 2008, 4:35 http://www.molecularpain.com/content/4/1/35
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inter-stimulus interval of 5 min. Thermal withdrawal
thresholds were determined as described by Hargreaves
[14] using the Plantar Test Apparatus, Stoelting, IL, US.
Responses to mechanical stimuli were measured with the
Automatic Von Frey apparatus from Ugo-Basile (Italy).
The ramp was set to reach the maximum stimulus (50 g)
in 20 sec.
Data analysis
For all data, statistical analysis was carried out on the raw
data using SPSS PC+. Changes in P-MeCP2, Zif268 and
Fos expression were quantified by immunohistochemis-
try. Immunopositive cells were counted in the dorsal horn
of CFA-injected animals (ipsi, 5 sections with maximum
response per animal). Data were analysed by general lin-
ear model univariate or multivariate test followed by LSD
post-hoc tests or Student's t-test, as appropriate.
For behaviour, the significance of any differences in
mechanical and thermal thresholds was assessed using
repeated measures two-way ANOVA (SPSS PC+). A signif-
icant effect on the main factor(s) was taken as the criterion
for progressing to post-hoc testing. 'Time' was treated as
'within subjects' factor and 'treatment' was treated as a
'between' subjects factor. Comparisons of changes in dif-
ferent groups of rats were carried out on time-matched
samples. When appropriate, the Greenhouse – Geisser 'ε'
correction was applied to correct for any violation of
sphericity of the variance – covariance matrix. Statistical
significance was set at P < 0.05.
Results
MeCP2 phosphorylation after CFA injection in the hind 
paw is maximum in lamina I-II and 1 h after CFA injection
We followed the changes in P-MeCP2 for up to 24 h after
injection of CFA in the hind paw (N = 3 at each time
point). Changes were only seen ipsilateral of the injection
and were mainly restricted to laminae I-II (see below and
Figure 1 and Figure 2). The only other significant changes
across the dorsal horn were seen in lamina 3–4, 6 h after
CFA injection (significant decrease in P-MeCP2 compared
to naïve from 17 ± 4 to 5.2 ± 0.4 immunopositive nuclei).
We compared the expression of P-MeCP2 with that of
Zif268 and Fos in laminae I-II across all time points (Fig-
ure 3 and Figure 4; N = 3/5 at each time point). The three
transcriptional regulators showed a similar pattern of acti-
vation in the medial area of the superficial dorsal horn.
There was a significant increase in P-MeCP2, Zif268 and
Fos from 30 min post CFA. Strikingly, for all genes, the
maximum changes were seen within 1 h to 2 h after CFA
administration. In laminae I-II, P-MeCP2 increased from
5 ± 1 to 32 ± 3 immunopositive nuclei (P < 0.001), Zif268
from 7 ± 1 to 74 ± 10 (P < 0.001) and Fos from 6 ± 1 to
61 ± 3 (P < 0.001) (Figure 3). There was no significant dif-
ference in the levels of P-MeCP2 between 1 h and 2 h, nor
of Zif268 or Fos. Although the levels of P-MeCP2 and
Zif268 seen 6 h after CFA were no different from that in
naïve animals, there was a significant upregulation in the
levels of P-MeCP2, Zif268 and Fos 24 h after CFA
(increase to 21 ± 3 immunopositive nuclei (P < 0.01), 31
± 8 immunopositive nuclei (P < 0.05) and 32 ± 1 (P <
0.01) respectively).
P-MeCP2 is co-expressed in neurones with Zif268 and Fos
We next investigated the potential overlap in neuronal
population expressing these transcription regulators in
laminae I-II. Tissue was taken at 1 h and 2 h after CFA and
sections were double-labelled for P-MeCP2 and Zif268,
and P-MeCP2 and Fos (N = 2/4 in each group). All images
of double stained dorsal horn tissue were acquired by con-
focal microscopy using a laser scanning microscope (Leica
TCS NT SP). A large population of neurones expressed
both P-MeCP2 and Zif268, and P-MeCP2 and Fos (Figure
5A and 5B). Interestingly, there was no difference in the
ratio of P-MeCP2 neurones expressing Zif268 at 1 h and 2
h (78% ± 5% and 76% ± 5%, respectively) whereas the
number of P-MeCP2 neurones expressing Fos increased
slightly with time (82% ± 2% at 1 h and 90% ± 1% at 2 h,
P < 0.05).
Time course of P-MeCP2 expression in the superficial dorsal  horn after CFA injection Figure 1
Time course of P-MeCP2 expression in the superfi-
cial dorsal horn after CFA injection. CFA injection in 
the hind paw significantly increased MeCP2 phosphorylation 
in the superficial dorsal horn, ipsilateral to the injection. 
Changes in P-MeCP2 expression were seen exclusively in 
Lamina I and II, with the exception of expression in Lamina 3 
to 4 at 6 h. Data show mean ± standard error of the mean. 
*P < 0.05, **P < 0.001, ***P < 0.0001, always vs naïve within 
the same dorsal horn area.
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Descending serotonergic inputs are essential for the full 
expression of P-MeCP2, Zif268 and Fos in the dorsal horn
Animals were separated in to 2 groups, one receiving an
intrathecal injection of saline and the other of 5,7-DHT
(N = 4/6 in each group). Seven days later, animals
received CFA and were sacrificed after 1 h. 5-HT staining
showed complete depletion of 5-HT in the superficial dor-
sal horn after 5,7-DHT, and GFAP and NeuN staining
indicated that 5,7-DHT did not cause glial proliferation or
hypertrophy or abnormal cell death (Figure 6). When ani-
mals received 5,7-DHT, there was a significant reduction
compared with saline in expression of P-MeCP2 ipsilat-
eral to the CFA injection (47 ± 4 vs 20 ± 2 immunopositive
nuclei; F1,10 = 37, P < 0.001), Zif268 (121 ± 14 vs 76 ± 7;
F1,10 = 11, P < 0.05) and Fos (81 ± 7 vs 59 ± 5; F1,10 = 8, P
< 0.05) in laminae I-II (Figure 7A and 7B).
When we plotted the mean number per dorsal horn sec-
tion, ipsilateral to the CFA injection, of P-MeCP2 positive
nuclei against the number of Zif268 or Fos positive nuclei
for individual animals for this experiment (N = 10), the
correlation was stronger between P-MeCP2 and Zif268
(correlation coefficient: R2 = 0.8) than between P-MeCP2
and Fos (R2 = 0.4), suggesting a parallel regulation for P-
MeCP2 and Zif268 (Figure 8).
Depletion of serotonergic axons in the dorsal horn reduces 
mechanical sensitivity but does not alter the thermal 
hyperalgesia that develops after CFA
We tested the hypothesis that the increase in pain sensitiv-
ity seen very early after the induction of an inflammation
state could be reduced by ablation of descending seroton-
ergic pathways. For this, animals were separated in 2
groups, one receiving an intrathecal injection of saline
and the other of 5,7-DHT. These 2 groups were further
divided into 2 groups, one dedicated to thermal testing (N
= 5/6) and the other to mechanical testing (N = 7/8) (ani-
mals were never tested in 2 different modalities). Animals
were all tested before and after intrathecal injections and
mechanical and heat thresholds were similar in the 2
treatment groups before CFA injection. Seven days after
the intrathecal treatment, animals received CFA into the
hind paw and their thresholds were measured 1 h, 3 h, 6
h and 24 h after injection. There was no effect of 5,7-DHT
on the heat threshold (Figure 9A). However depletion of
5-HT significantly attenuated the decrease in mechanical
Expression of P-MeCP2 in the superficial dorsal horn after CFA injection Figure 2
Expression of P-MeCP2 in the superficial dorsal horn after CFA injection. Pictures show typical P-MeCP2 immuno-
reactivity in the dorsal horn, ipsilateral to the injection, 30 min, 1 h and 2 h after CFA injection in the hind paw. Scale bars, top: 
100 μm; bottom: 50 μm.
30min 1h 2h
Time course of MeCP2 phosphorylation after CFA injection
Expression of P-MeCP2, Zif268 and Fos in the superficial  dorsal horn after CFA injection Figure 3
Expression of P-MeCP2, Zif268 and Fos in the super-
ficial dorsal horn after CFA injection. There was a sig-
nificant effect of CFA on MeCP2 phosphorylation and Zif268 
and Fos expression, with maximum changes at 1 h and 2 h. 
Data show mean ± standard error of the mean. *P < 0.05, **P 
< 0.001, ***P < 0.0001, always vs naïve for each of the tran-
scription regulator.
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threshold seen after the induction of inflammation from
1 h after CFA. The response was still attenuated 24 h later
(overall ANOVA: F1,13 = 7.2, P < 0.05) (Figure 9B).
Discussion
Noxious stimulation of the periphery leads to a large
number of rapid post-translational and transcriptional
changes in dorsal horn neurones. We show that the acti-
vation or expression of the transcription factors MeCP2,
Zif268 and Fos after primary afferents stimulation depend
on convergent input from primary afferents and descend-
ing pathways from the brain.
Time course of molecular and behavioural changes in a 
model of inflammation
The phosphorylation of MeCP2 in dorsal horn neurones
following CFA was surprisingly slow compared to other
transcription regulators such as cAMP response element-
binding (CREB) and extracellular signal-regulated kinase
(ERK) which are phosphorylated in dorsal horn neurones
within 5 min of peripheral nociceptive stimulation
[15,16]. However, the time course of phosphorylation of
MeCP2 closely paralleled that of Zif268 and Fos expres-
sion, suggesting a common time course of regulation of
gene expression for these 3 transcription factors. Moreo-
ver, there was a strong correlation between the changes in
transcription factors activation and animal behaviour
from 30 min to 2 h after CFA, supporting the idea that
macromolecular changes could contribute to this early
behavioural change.
Time course of Zif268 expression in the superficial dorsal horn after CFA injection Figure 4
Time course of Zif268 expression in the superficial dorsal horn after CFA injection. Pictures show typical Zif268 
immunoreactivity in the dorsal horn, ipsilateral to the injection, before (naïve) and 30 min, 1 h, 2 h, 6 h and 24 h after CFA 
injection in the hind paw. Scale bars, 50 μm.
Naïve 30min 1h
2h 6h 24h
Time course of Zif268 activation after CFA injection
P-MeCP2 is expressed in sub-populations of Zif268 and Fos  expressing neurones after CFA injection Figure 5
P-MeCP2 is expressed in sub-populations of Zif268 
and Fos expressing neurones after CFA injection. Tis-
sue was taken 1 h after CFA injection. Spinal cord sections 
were double-labelled with antibodies against P-MeCP2 
(green) and A/ Zif268 (red) or B/ Fos (red). Double labelling 
resulted in yellow staining (arrows). Images were taken using 
confocal microscopy. Scale bars, 20 μm.
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Early post-translational changes are clearly important in
the initial phases of sensitization [17,18]. However, trans-
lation following new gene transcription or from mRNA
already present in neuronal cell bodies and their processes
is necessary for maintaining the central sensitization that
follows peripheral noxious stimulation. Such process can
also participate to the early phases of sensitizition.
Indeed, recent studies showed that protein synthesis in
the dorsal horn contributes to the increase in mechanical
sensitivity seen after noxious stimulation from 30 min
post stimulation [19,20].
Intrathecal 5,7-DHT causes serotonin depletion but no glial  proliferation or cell death Figure 6
Intrathecal 5,7-DHT causes serotonin depletion but 
no glial proliferation or cell death. Tissue was taken 7 
days after 5,7-DHT treatment and dorsal horn sections were 
stained for 5-HT, GFAP and NeuN. 5-HT staining confirmed 
a complete depletion of 5-HT in the superficial dorsal horn 7 
days after 5,7-DHT, and GFAP and NeuN staining indicated 
that, at the concentration used in this study, 5,7-DHT did not 
cause glial proliferation or hypertrophy or abnormal cell 
death. Scale bar, 50 μm.
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NeuN
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NeuN
GFAP
5,7-DHT treatment reduces CFA-induced P-MeCP2, Zif268  and Fos expression Figure 7
5,7-DHT treatment reduces CFA-induced P-MeCP2, 
Zif268 and Fos expression. Seven days after 5,7-DHT or 
saline treatment, animals received CFA and were sacrificed 
after 1 h. A/ P-MeCP2, Zif268 and Fos expression 1 h after 
CFA injection in the hind paw were significantly reduced by 
5,7-DHT. N = 4/6 in each group. Data show mean ± standard 
error of the mean; *P < 0.05, ***P < 0.0001. B/ Pictures show 
typical P-MeCP2 immunoreactivity in the dorsal horn, ipsilat-
eral to the injection, 1 h after CFA injection in the hind paw. 
5,7-DHT reduced P-MeCP2 immunoreactivity compared to 
saline, especially in the medial area of the superficial dorsal 
horn. Scale bars, 40 μm.
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It seems likely that the expression of P-MeCP2, Zif268 and
Fos is part of an early cascade of molecular events that lead
to changes in gene expression required for both the initi-
ation and maintenance of pain states. This is supported by
our recent study where the mechanical hypersensitivity
seen in an animal model of arthritis remained maximum
from 6 h to 7 days after CFA injection, while the pattern
of gene expression differed throughout the time course
studied [7].
Molecular changes in superficial dorsal horn modulated by 
descending pathways
We found that phosphorylation of MeCP2 that follows
CFA injection was decreased by serotonin depletion. We
have previously reported that, after induction of periph-
eral joint inflammation, MeCP2 was phosphorylated in
rat superficial dorsal horn and lamina I/III projection neu-
The correlation between P-MeCP2 and Zif268 regulation is  stronger than that between P-MeCP2 and Fos Figure 8
The correlation between P-MeCP2 and Zif268 regu-
lation is stronger than that between P-MeCP2 and 
Fos. The graphs represent the mean number of Zif268 (A) 
or Fos (B) expressing neurones per dorsal horn section, ipsi-
lateral to the CFA injection, per individual animal, against the 
number of P-MeCP2 immuno-positive neurones. The corre-
lation is considerably stronger between P-MeCP2 and Zif268 
(correlation coefficient: R2 = 0.8) than that between P-
MeCP2 and Fos (R2 = 0.4), suggesting a parallel regulation for 
P-MeCP2 and Zif268.
y = 0.44x - 10.9
R2 = 0.8
0
10
20
30
40
50
60
0 30 60 90 120 150 180
y = 0.59x - 9.1
R2 = 0.4
0
10
20
30
40
50
60
0 30 60 90 120 150 180
A
B
Zif268
Fos
P
-
M
e
C
P
2
P
-
M
e
C
P
2
Mean number of transcription factor expressing neurones per dorsal
horn section, ipsilateral to the CFA injection, per individual animal
Saline
5,7DHT
Saline
5,7DHT
5,7-DHT attenuates mechanical sensitivity but not thermal  sensitivity Figure 9
5,7-DHT attenuates mechanical sensitivity but not 
thermal sensitivity. Seven days after 5,7-DHT or saline 
treatment, animals received CFA in the hind paw. A/ 5,7-
DHT did not change the increased thermal sensitivity seen 
after CFA injection in the hind paw as measured by the Har-
greaves test. N = 5/6.B/ 5,7-DHT significantly attenuated the 
inflammation-induced decrease in mechanical threshold 
measured by the automatic Von Frey from 1 h after CFA 
injection. The response was still attenuated 24 h later. N = 7/
8. For A, and B, data show mean ± standard error of the 
mean; *P < 0.05, **P < 0.001.
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rones, and that expression of SGK1, a protein under tran-
scriptional repression by MeCP2, also expressed in lamina
I/III projection neurones, increased in the superficial dor-
sal horn in an inflammatory pain state [7]. Antisense
knock down of this protein delayed the onset of the
increased mechanical sensitivity seen in a state of inflam-
mation, strongly supporting a role for MeCP2 in the initi-
ation, and possibly maintenance, of pain states. In the
present study, we were able to show that serotonin deple-
tion attenuated both MeCP2 activation and the increased
mechanical sensitivity that follows CFA injection, again
strengthening the correlation between transcription fac-
tors activation and changes in behaviour.
We also report that serotonin depletion reduced inflam-
mation-induced Fos. Although controversial, recent
research using antisense approaches to deplete dorsal
horn Fos protein levels has largely indicated that Fos
induction leads to increased pain sensitivity particularly
during the second phase of the formalin test [21-23].
Moreover, up-regulation of dynorphin A, which has been
shown to be pronociceptive by acting at the bradykinin
receptors (B1/2) on primary afferents [24], was linked to
Fos expression [25].
Expression of inflammation-induced Zif268 was also
attenuated after serotonin depletion, in parallel with
mechanical sensitivity. Nociceptive stimulus-specific
expression of Zif268 was shown to be required for the
maintenance of long-term potentiation (LTP) and spatial
learning in the hippocampus [8]. We also recently pro-
posed a role for Zif268 in maintaining the increased sen-
sitivity of spinal neurones in inflammatory pain
condition [9].
Here, we found that a large population of P-MeCP2
immunopositive nuclei were also expressing Fos (82–
90%) and Zif268 (76–78%). The possibility that Fos is a
target gene for MeCP2 has been excluded by previous in
vitro  studies [6] and recent studies of gene expression
changes in brain tissue of MeCP2 deficient mice failed to
report any changes in Fos and Zif268 mRNA [26]. How-
ever, it is well accepted that MeCP2 activity is extremely
cell type specific and therefore we cannot exclude a possi-
ble direct interaction between MeCP2 and Fos or/and
Zif268 promoter region within superficial dorsal horn
neurones. Evidence also suggests that an increase in P-
MeCP2 may lead to a persistent up-regulation of Fos as
seen here at 6 h and 24 h following CFA. Phosphorylation
of MeCP2 has been shown to de-repress BDNF expression
[27], an increase in BDNF mRNA has been found in the
dorsal horn after CFA injection [28] and intrathecal BDNF
challenge has been shown to induce the transcription of c-
fos within 90 min [29].
Lamina I projecting neurones
Crucially, P-MeCP2, Zif268 and Fos are all up-regulated in
lamina I, NK1 positive, projection neurones following
peripheral noxious stimulation: after peripheral inflam-
mation 47% and 27% of projection neurones expressed
Zif268 [30] and P-MeCP2 [7] respectively. However only
10% of NK1 expressing neurones expressed Fos, irrespec-
tively of the noxious stimulation (skin, joint, muscle,
inflammation and nerve injury) [31], strongly suggesting
that Zif268 and P-MeCP2 are more generally expressed in
NK1-positive projections neurones than Fos.
Lamina I neurones project to the brainstem and thalamus,
indirectly activate descending pathways to the dorsal horn
and are essential for the full development of pain states
[32,33]. Our present findings suggest that the transcrip-
tion regulators that contribute to the plasticity of projec-
tion neurones that engage descending pathways are
themselves regulated by these descending controls. This
suggests that the initiation and/or maintenance of pain
states depend on feedback loop mechanisms and support
the idea that regulation of gene expression in lamina I
projection neurones is key to the molecular control of
pain sensitivity.
Descending serotonergic control of pain thresholds
We report that ablation of serotonergic innervation of the
lumbar dorsal horn attenuates increased mechanical but
not thermal sensitivity in an inflammatory pain state.
How might this dissociation have been achieved? Inflam-
matory pain states are dependent upon changes in both
peripheral nociceptors and neurones in the superficial
dorsal horn. In other words, the amplification of the
response to thermal or mechanical stimulation of
inflamed tissue can be due to peripheral or/and central
sensitization. Previous research has identified clear
peripheral thermal sensitization of primary afferents noci-
ceptors following inflammation but mechanical sensitiza-
tion of cutaneous afferents has been rather more
controversial. Andrew and Greenspan (1999) conclude
that mechanical sensitization of primary afferents by
inflammatory agents does indeed occur but is only uncov-
ered by supramaximal mechanical stimulation [34]. In
the present study, behavioural assessment did not use
supramaximal stimulation and most of the amplification
of the response to mechanical stimulation of inflamed tis-
sue would have been largely due to central sensitization.
Our results therefore suggest that central sensitization that
leads to increased mechanical sensitivity is depressed by
serotonergic lesions. Whether thermal sensitivity is mod-
ulated by central sensitization in the same way would be
more difficult to assess with behavioural techniques but
distant secondary thermal changes are reported to be sen-
sitive to manipulations of the RVM [35-37].Molecular Pain 2008, 4:35 http://www.molecularpain.com/content/4/1/35
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Serotonin Receptor Mechanisms
There is evidence for both inhibitory and facilitatory sero-
tonergic and non-serotonergic inputs to the dorsal horn
[2,10,38,39]. Our present findings, along with a number
of previous reports [1,12,40,41], highlight the importance
of a serotonergic descending facilitatory system. Facilita-
tory actions of spinal serotonin have been shown to
engage the 5-HT3 receptor (5-HT3-R) [12,40] which is
predominantly found on primary afferent axons and
axons of dorsal horn neurones [42]. However, the
mechanical hypersensitivity that develops after CFA injec-
tion did not differ between 5-HT3-R mutant and wild-type
mice [43]. Other serotonergic receptors have also been
linked with descending serotonergic facilitation and
would also deserve attention: e.g. 5-HT2A [44], 5-HT7
[45], 5-HT1A, 5-HT2C and 5-HT4 receptors [13].
The balance between descending inhibition and excita-
tion is a crucial one: descending facilitation must be tonic
over long periods of time to maintain the sensitivity
around the site of injury during healing, preventing fur-
ther damage, while descending inhibition is crucial for the
short lasting expression of endogenous analgesia required
during conflict or when an animal in pain needs to move
to acquire food and water.
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